1. China Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Shanghai Pioneer Holding Ltd

Shanghai Pioneer Holding Ltd

HHKEX:1345
1.99
HKD
-0.08
(-4.11%)
2.73BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.21
1.16
1.11
1.38
1.67
1.3
1.08
1.1
1.19
1.31
1.33
1.32
1.11
- -
Basic EPS, GAAP
0.23
0.2
0.13
0.18
0.22
0.07
0.09
0.04
0.12
0.2
0.12
0.13
0.1
- -
Free Cash Flow per Basic Share
0.03
-0.05
0.23
0.26
0.17
0.1
0.22
- -
0.18
0.02
-0.14
0.14
0.16
- -
Dividend per Share
0.22
0.19
0.14
0.11
0.17
- -
- -
0.18
0.11
0.07
0.07
0.07
0.11
- -
Book Value per Share
0.87
0.85
0.75
0.83
0.86
0.86
0.91
0.72
0.72
0.8
0.86
0.96
0.91
0.96
Tangible Book Value per Share
0.86
0.69
0.7
0.82
0.85
0.85
0.9
0.68
0.68
0.77
0.83
0.94
0.89
0.94
Basic Weighted Avg Shares
1,047
1,333
1,313
1,295
1,290
1,250
1,219
1,211
1,203
1,191
1,178
1,164
1,153
1,165
Sales/Revenue/Turnover
1,272
1,540
1,461
1,790
2,154
1,624
1,316
1,332
1,435
1,556
1,567
1,531
1,283
- -
Operating Margin (%)
22.59
18.89
20
15.13
14.18
9.91
12.31
8.04
13.15
15.36
11.5
14.58
11.3
- -
Depreciation Expense
2
8
17
13
8
8
9
8
13
14
19
31
33
- -
Net Income, GAAP
238
262
174
237
279
85
105
52
143
235
139
152
114
- -
Effective Tax Rate (%)
13.48
14.35
16.58
15.49
9.28
20.86
30.07
45.99
30.1
21.92
28.5
31.77
29.13
- -
Profit Margin (%)
18.74
16.99
11.93
13.26
12.95
5.21
7.95
3.94
9.94
15.12
8.84
9.9
8.91
- -
Working Capital
1,036
789
761
814
851
753
835
643
665
662
664
658
673
658
LT Debt
- -
9
15
11
5
- -
- -
- -
- -
8
13
11
62
11
Total Equity
1,157
1,226
996
1,111
1,141
1,106
1,144
912
911
1,022
1,018
1,116
1,045
1,116
Return on Invested Capital (%)
21.35
14.62
11.69
19.31
23.21
6.44
7.99
4.83
14.33
21.01
11.69
12.32
6.81
- -
Return on Capital (%)
22.74
16
12.26
19.27
23.46
7.16
9.02
5.09
15.67
24.38
14.59
13.97
10.64
- -
Return on Common Equity (%)
34.81
22.91
16.4
22.52
24.78
7.54
9.32
5.11
15.7
24.56
13.75
14.32
10.59
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
61
70
64
LT Borrowings
- -
- -
- -
LT Finance Leases
13
13
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,174
1,167
1,159
Market Capitalization
1,953
2,172
2,562

Working Capital

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
1,107
1,041
934
Cash, Cash Equivalents & STI
124
145
104
Accounts Receivable, Net
448
418
337
Inventories
418
323
321
Total Current Liabilities
443
323
275
Payables & Accruals
- -
- -
- -
ST Debt
61
70
64
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.93%
3%
-6.31%
Free Cash Flow
-530.33%
-1,049.2%
12.29%
Net Income, GAAP
13.85%
36.14%
-24.56%
Sales/Revenue/Turnover
-0.11%
-0.32%
-16.17%
Total Cash Common Dividend
- -
-3.9%
63.56%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,567
2024
- -
- -
1,531
2025
- -
- -
1,283

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.12
2024
- -
- -
0.13
2025
- -
- -
0.1

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.07
2024
- -
- -
0.07
2025
- -
- -
0.11

Company Description

Company Profile APIChatGPT
CEO
Yuewen Yang
Full Time Employees
364
Sector
Distribution services
Industry
Medical distributors
Address
No.15, Lane 88 Wuwei Road Shanghai SH China 200331
IPO Date
Nov 5, 2013
Website
pioneer-pharma.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Shanghai Pioneer Holding Ltd (1345.HK) is an investment holding company primarily engaged in the marketing, promotion, sales, and channel management of imported pharmaceutical products and medical devices in China. The company offers a portfolio of pharmaceutical products covering ophthalmology, pain management and anti-inflammatory analgesia, cardiovascular, gastroenterology, immunology, gynecology, respiratory, and other therapeutic areas; medical devices spanning ophthalmology, orthopedics, odontology, wound care, and dental devices; as well as ancillary tools, imported in-licensed prescription products, and personal protective equipment, which it sells to hospitals, medical institutions, and pharmacies nationwide through comprehensive marketing services and pipeline arrangements. Founded in 1996 and headquartered at No. 15, Lane 88 Wuwei Road, Putuo District, Shanghai, China, the company maintains long-term partnerships with international suppliers in North America, Europe, Australia, and Spain; it is a subsidiary of Pioneer Pharma (BVI) Co., Ltd., operates solely in the domestic Chinese market, and listed on the Hong Kong Stock Exchange's main board in November 2013. In recent years, Shanghai Pioneer Holding Ltd has pursued industrial chain extension through investments in overseas partners including NovaBay (US biopharmaceuticals), Paragon (Australian medical devices), Worldpathol (Spanish animal vaccines), DMAX Co. (US$3 million stake in 2020), and Shanghai Yuhan fund; established the Chongqing Rongchang Production Base for diversification; and changed its name from China Pioneer Pharma Holdings Limited following registration with Hong Kong's Companies Registry. As of June 30, 2025, the company reported first-half gross profit of RMB303 million and declared an ordinary interim dividend, reflecting ongoing operational stability amid its globalization and R&D investment strategies.